Despite multiple approved therapies for the management of Eosinophilic asthma (EA), approximately half the patients do not respond to treatment and OCS tapering remains challenging. 11 assets are in clinical development for EA although in the past year, multiple therapies failed in Phase II clinical trials for severe asthma.

Click here to learn more: Eosinophilic Asthma